Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:UROV

Urovant Sciences (UROV) Stock Price, News & Analysis

Urovant Sciences logo

About Urovant Sciences Stock (NASDAQ:UROV)

Key Stats

Today's Range
$16.24
$16.24
50-Day Range
$16.19
$16.24
52-Week Range
$7.15
$16.26
Volume
N/A
Average Volume
114,469 shs
Market Capitalization
$531.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

Receive UROV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Urovant Sciences and its competitors with MarketBeat's FREE daily newsletter.

UROV Stock News Headlines

Could This Tiny Device Help You Make an Extra $30k a Year?
I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.
PM360 Announces 2023 Trailblazer Award Winners
See More Headlines

UROV Stock Analysis - Frequently Asked Questions

Urovant Sciences Ltd. (NASDAQ:UROV) issued its quarterly earnings results on Thursday, February, 11th. The company reported ($1.46) earnings per share for the quarter, beating analysts' consensus estimates of ($1.59) by $0.13.

Urovant Sciences (UROV) raised $150 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Urovant Sciences investors own include Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), Idera Pharmaceuticals (IDRA) and Kaleido Biosciences (KLDO).

Company Calendar

Last Earnings
2/11/2021
Today
12/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:UROV
Fax
N/A
Employees
70
Year Founded
N/A

Profitability

Net Income
$-146,740,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.90) per share

Miscellaneous

Free Float
N/A
Market Cap
$531.75 million
Optionable
Not Optionable
Beta
2.36
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:UROV) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners